How do the AMAROS trial results change practice?

The Lancet Oncology

Volumn 15, Issue 12, 2014, Pages 1280-1281

  Boughey, Judy C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; DISTANT METASTASIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HIGH RISK PATIENT; HUMAN; INCIDENCE; JOINT MOBILITY; LOCAL METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; PRACTICE GUIDELINE; PREDICTION; PRIMARY TUMOR; QUALITY OF LIFE; RECURRENCE RISK; RISK REDUCTION; SENTINEL LYMPH NODE BIOPSY; BREAST NEOPLASMS; FEMALE; LYMPH NODE; LYMPHATIC METASTASIS; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS;

EID: 84908563374     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71018-6     Document Type: Note

References (5)

1. Donker M, van Tisenhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014, published online Oct 16. http://dx.doi.org/10.1016/S1470-2045(14)70460-7.
2. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305:569-575.
3. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010, 252:426-432.
4. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013, 14:297-305.
5. Clinical practice guidelines in oncology: breast cancer National Comprehensive Cancer Network, (accessed Oct 9, 2014). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.